• 1
    Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964; 1: 8992.
  • 2
    de Lange T, Larsen S, Aabakken L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol. 2004; 4: 9.
  • 3
    D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763786.
  • 4
    Orlandi F, Brunelli E, Feliciangeli G, et al. Observer agreement in endoscopic assessment of ulcerative colitis. Ital J Gastroenterol Hepatol. 1998; 30: 539541.
  • 5
    Rutgeerts P, Colombel JF, Reinisch W, et al. Infliximab induces and maintains mucosal healing in patients with active ulcerative colitis: the ACT trial experience. Gut. 2005; 54(suppl VII): A8.
  • 6
    Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412422.
  • 7
    Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007; 56: 453455.
  • 8
    Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005; 352: 24992507.
  • 9
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 16251629.
  • 10
    Carrasco JL, Jover L. Estimating the generalized concordance correlation coefficient through variance components. Biometrics 2003; 59: 849858.
  • 11
    Walsh AJ, Brain O, Keshav S, et al. How variable is the Mayo score between observers and might this affect trial recruitment or outcome? Gastroenterology. 2009; 136(suppl 1): A677.
  • 12
    Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002; 97: 13981407.
  • 13
    Maunder RG, Greenberg GR. Comparison of a disease activity index and patients' self-reported symptom severity in ulcerative colitis. Inflamm Bowel Dis. 2004; 10: 632636.
  • 14
    Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007; 133: 423432.